Sequenom To Begin Clinical Assessment Of Noninvasive Screening Technology For Down Syndrome
Jan 29th 2008Drug InformationPediatrics
Sequenom, Inc. (NASDAQ:SQNM) announced the approval of a protocol by the Institutional Review Board (IRB) at San Diego-based Sharp HealthCare, clearing the way to commence patient enrollment in a screening study to clinically assess the Company’s noninvasive cell free fetal nucleic acid SEQureDx? Technology for the detection of fetal aneuploidy, including Down syndrome, using a laboratory developed test (LDT). More than 2.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
